Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

June 28, 2004 28 June, 2004

Pheromone Sciences' Fertility Monitor Commercial Order Issued

Toronto, Ontario (June 28, 2004) -- Pheromone Sciences Corp. (TSX Venture: PHS), a Toronto based biotech company and the developer of the Fertilit�©-OV(tm) monitoring device is pleased to announce that HealthWatchSystems, the proposed purchaser of the Fertility Monitor technology, has placed its first commercial-scale order for the manufacture of Fertility Monitor units in anticipation of their launching the product throughout North America when all the preparations are complete.

This order when delivered will lead to royalty payments from HealthWatchSystems to Pheromone Sciences once the sales start.

In addition Ningxia St. Edenweiss will soon place their initial order for the product and commence its preliminary pre launch marketing activities, upon receipt of the marketing approval from the regulatory agencies of China. As previously announced, Ningxia St Edenweiss, is a public company whose shares are traded on China's Shenzhen Stock Exchange (symbol 000982) has obtained marketing and distribution rights for Pheromone's Fertilit�©- OV monitor in China, Hong Kong, Macao and Taiwan in August of 2003. Ningxia St Edenweiss is a manufacturing and marketing company with well-established relationships throughout the Chinese medical community.

"This manufacturing order is very gratifying to us all and it represents a significant milestone for both Pheromone Sciences and HEATHWATCHSYSTEMS INC.", stated Christopher Neuman, President and CEO of Pheromone.

The Fertilit�©-OV monitor is a FDA approved fertility cycle monitoring device for the consumer and professional medical market and provides a reliable "predictive" approach to natural, cycle-based family planning. The Fertilit�©-OV monitor is a non-invasive method of predicting the fertility window and ovulation date through the measurements of perspiration ion changes on the surface of the skin through a unique combination of bio- sensing and computer technologies These changes in female perspiration allow for the prediction of ovulation up to 4 days before the ovulation day.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.